Tetranectin (TN) is a plasminogen-binding protein found in human serum. Although it has been suggested to be closely related to various stem cell differentiation, including myogenesis, the role of TN in muscle development remains unclear. In this study, we identified TN as an anti-myogenic factor during the differentiation of C2C12 satellite cells. The exogenous supplementation of TN inhibited myogenic differentiation, whereas differentiation was significantly enhanced in the TN-depleted medium. Epigallocatechin-3-gallate (EGCG), a catechin abundant in green tea, significantly enhanced myogenic differentiation by reducing TN levels in the medium and downregulating TN gene expression during the differentiation process. These results demonstrate that EGCG promotes myogenesis by inhibiting TN at both the transcriptional and functional levels, highlighting TN as a promising therapeutic target for muscle regeneration disorders.
Tetranectin (TN), also known as C-type lectin domain family 3 member B (CLEC3B), is a secreted glycoprotein originally identified through its high-affinity interaction with plasminogen. Although initially linked to fibrinolysis, TN is now increasingly recognized as an extracellular regulator associated with matrix remodeling, bone development, tissue repair, and disease-related proteolytic processes. Dysregulated TN expression has been reported in a broad range of pathological conditions, including cancer, cardiovascular disease, inflammatory disorders, and neurodegenerative states. In this review, we summarize current knowledge of TN with emphasis on its molecular architecture, ligand-binding properties, trimeric organization, and regulatory mechanisms. We further discuss its context-dependent biological functions, with particular attention to how tissue-specific and compartment-specific TN patterns may influence disease progression and clinical interpretation, especially in oncology. In addition, we evaluate the evidence supporting TN as a diagnostic and prognostic biomarker and consider its emerging therapeutic relevance. Finally, we outline the major challenges that currently limit clinical translation and highlight key directions for future investigation.